Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov-Dec;9(6):153-7.
doi: 10.1111/j.1535-7511.2009.01326.x.

Extended-release formulations of antiepileptic drugs: rationale and comparative value

Emilio Perucca  1
Affiliations

Extended-release formulations of antiepileptic drugs: rationale and comparative value

Emilio Perucca. Epilepsy Curr. 2009 Nov-Dec.

Abstract

Extended-release products are designed to prolong the absorption of drugs with short half-lives, thereby allowing longer dosing intervals while minimizing fluctuations in serum drug levels. The relationship between serum drug concentration and clinical effects of antiepileptic drugs (AEDs) can be complex and reducing fluctuations in serum drug levels is not equally advantageous for all AEDs. Extended-release formulations have been shown to be particularly valuable for carbamazepine, whereas for other AEDs advantages, other than prolongation of the dosing interval, have not been clearly demonstrated. Differences in bioavailability may exist between extended-release and immediate-release formulations and among different brands of extended-release products. Therefore, when switching from one formulation to another, careful monitoring of clinical response and attention to the need for dose adjustment are warranted.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Comparative effectiveness of lamotrigine and carbamazepine (expressed as the percentage of patients retained in the trial at the end of the assessment period) in two randomized, double-blind trials among patients aged 65 years or older with new-onset epilepsy. Duration of follow-up was 24 weeks in trial A and 40 weeks in trial B. The two trials had a very similar design and identical twice-daily dosing regimens, but carbamazepine was administered in an immediate-release (IR) formulation in trial A and in extended-release (ER) formulation in trial B. Abbreviations: IR, immediate release; ER, extended release; N, number of subjects in the intent-to-treat population. References:*39, †40.
See this image and copyright information in PMC

References

    1. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: A position paper by the Subcommission on therapeutic drug monitoring, ILAE Commission on therapeutic strategies. Epilepsia. 2008;49:1239–1276. - PubMed
    1. Pellock JM, Smith MC, Cloyd JC, Uthman B, Wilder BJ. Extended-release formulations: Simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav. 2004;5:301–307. - PubMed
    1. Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs. 2007;21:765–774. - PubMed
    1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310. - PubMed
    1. Löscher W, Frey HH. Kinetics of penetration of common antiepileptic drugs into cerebrospinal fluid. Epilepsia. 1984;25:346–352. - PubMed